Bristol Myers Squibb (BMY) Total Debt (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Total Debt data on file, last reported at $44.5 billion in Q1 2026.

• Total Debt for Q1 2026 came in at $44.5 billion, down 10.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.5 billion (down 10.56% YoY), and the FY2025 annual result was $45.1 billion, down 9.14% from the prior year.
• Total Debt eased to $44.5 billion in Q1 2026 per BMY's latest filing, from $45.1 billion in the prior quarter.
• Over five years, Total Debt peaked at $55.7 billion in Q1 2024 and troughed at $37.6 billion in Q3 2023.
• A 5-year average of $44.9 billion and a median of $45.0 billion in 2022 frame the typical range for Total Debt.
• The sharpest annual moves came in 2023 and 2024: Total Debt retreated 15.88% in 2023, then surged 47.18% in 2024.
• A 5-year view of Total Debt shows it stood at $39.3 billion in 2022, then advanced by 1.15% to $39.8 billion in 2023, then advanced by 24.83% to $49.6 billion in 2024, then fell by 9.14% to $45.1 billion in 2025, then retreated by 1.44% to $44.5 billion in 2026.
• Business Quant data shows BMY's Total Debt at $44.5 billion in Q1 2026, $45.1 billion in Q4 2025, and $49.0 billion in Q3 2025.